Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeljanz in TNF-refractory Psoriatic Arthritis (OPAL BEYOND)
NCT01882439Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in psoriatic arthritis (PsA), sponsored by Pfizer. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01882439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882439.